Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC. (MRK)

106
Delayed Quote. Delayed Nyse - 04/23 02:31:00 pm
57.225 USD   -0.94%
48m ago Novartis-GSK asset swap offers template for pharma and beyond
1d ago Novartis, Valeant bids herald new deal-making era for pharma
1d agoDJGlaxo Exits Cancer Drugs
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

12/20/2012 | 09:17am US/Eastern
Recommend:
0
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at Tess.Stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
Recommend :
0
React to this article
Latest news on MERCK & CO., INC.
48m ago Novartis-GSK asset swap offers template for pharma and beyond
1d ago Novartis, Valeant bids herald new deal-making era for pharma
1d agoDJGlaxo Exits Cancer Drugs
2d ago AstraZeneca cancer pipeline seen as draw for Pfizer
6d ago MERCK : FDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allerge..
6d ago MERCK : FDA OKs Merck tablet to reduce ragweed allergies
6d agoDJEuropean Regulator Warns of More Drug Tampering
6d ago MERCK : Study Findings from Merck & Company Provide New Insights into Connective..
7d ago MERCK : Findings from Merck & Company in the Area of Adenosine Therapy Described
04/16 Reckitt leans towards pharmaceuticals spin-off
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
Merck _ Co., Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF